This segment focuses on providing comprehensive drug discovery services to pharmaceutical and biotechnology companies. Research and development activities include assay development and screening, medicinal and synthetic chemistry, computer-aided drug design, structural biology, in vitro/in vivo pharmacology, ADME/DMPK studies, and analytical testing. The segment utilizes advanced technologies such as high-throughput screening, computational chemistry, and various in vitro and in vivo models. Therapeutic areas covered include oncology, immunology, and other areas with high unmet medical needs. The impact on patients is through the acceleration of drug development, leading to potentially life-saving treatments. Selvita's market positioning is as a leading preclinical CRO, offering integrated drug discovery solutions. Future opportunities include expanding into new therapeutic areas and leveraging AI/ML for drug design. Regulatory and clinical aspects are supported through services like batch release for clinical trials. Partnerships and collaborations are key to expanding the service portfolio and entering new fields, such as biologic drug discovery.

This segment offers a range of services to support the development of new drugs, including drug testing and bioanalytical analysis. Research and development activities include development and optimization of analytical methods, validation and transfer of methods, stability studies, quality control, and regulatory support. The segment utilizes advanced analytical techniques and adheres to stringent quality standards. Therapeutic areas include a broad range of diseases, with a focus on ensuring the safety and efficacy of new drug candidates. The impact on patients is through the provision of high-quality data to support clinical trials and regulatory submissions. Selvita's market positioning is as a reliable partner for drug development, offering expertise in bioanalytical and regulatory aspects. Future opportunities include expanding into new areas of drug development and providing integrated solutions. Regulatory and clinical aspects are central to this segment, with services designed to meet the requirements of regulatory bodies. Partnerships and collaborations are essential for providing comprehensive drug development support.

This segment provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Research and development activities include the development of AI-based platforms for drug discovery and high-content screening. The segment utilizes advanced technologies such as machine learning, artificial intelligence, and data analytics. Therapeutic areas include a broad range of diseases, with a focus on accelerating drug discovery and improving patient outcomes. The impact on patients is through the acceleration of drug development and the identification of new drug targets. Selvita's market positioning is as a provider of cutting-edge bioinformatics solutions. Future opportunities include expanding into new areas of data science and providing integrated solutions. Regulatory and clinical aspects are supported through data analysis and interpretation. Partnerships and collaborations are key to expanding the service portfolio and entering new fields.